摘要
目的探讨FOLFOX方案经肝动脉灌注化疗治疗晚期原发性肝细胞癌的临床疗效。方法40例经临床确诊后行FOLFOX方案治疗的晚期原发性肝癌患者分为对照组和实验组两组,对照组的FOLFOX方案行常规静脉化疗,实验组的FOLFOX方案经至少1个疗程的肝动脉灌注化疗,评价其治疗效果。结果对照组中位随访时间8.5个月(2.2~11.8个月),无进展生存时间(progression free survival,PFS)为8.7个月(95%CI:6.3~10.3个月),总生存率(overall survival rate,OS)为9.8个月(95%CI:8.3~10.1个月);累计1年生存率为60%。实验组所有患者肿瘤大小都有不同程度的缩小,其完全缓解率及部分缓解率都有不同程度的提高,患者中位随访时间8.9个月(2.3~12.9个月),中位疾病无进展生存时间为9.5个月(95%CI:6.5~10.8个月),OS为10.9个月(95%CI:8.6~11.5个月);累计1年生存率为80%。实验组与对照组相比,不良反应发生率显著减低。结论对晚期肝癌患者的FOLFOX方案行经肝动脉灌注化疗是一项更加高效的治疗方法,值得临床进一步推广。
Objective:To explore the clinical efficacy of FOLFOX regimen via hepatic artery infusion chemotherapy in the treatment of advanced primary hepatocellular carcinoma.Methods:Forty patients with advanced primary liver cancer were divided into two groups:experimental group and control group.The experimental group received at least one course of hepatic artery infusion chemotherapy(FOLFOX program),while the control group received routine intravenous chemotherapy(FOLFOX program),and the therapeutic effect was evaluated.Results:The tumor size of all patients in the experimental group was reduced in different degrees,and the complete and partial remission rates were improved in different degrees.The median follow-up time of the control group was 8.5 months(2.2-11.8 months),the median disease progression free survival(PFS)time was 8.7 months(95%CI:6.3-10.3 months),overall survival rate(OS)was 9.8 months(95%CI:8.3-10.1 months),and the cumulative 1-year survival rate was 60%.The median follow-up time of patients was 8.9 months(2.3-12.9 months),PFS was 9.5 months(95%CI:6.5-10.8 months),and OS was 10.9 months(95%CI:8.6-11.5 months).The cumulative 1-year survival rate was 80%.Conclusion:The FOLFOX regimen for patients with advanced liver cancer through hepatic arterial infusion chemotherapy is a more efficient treatment method and is worthy of further clinical promotion.
作者
李伟
张良杰
李冬冬
赵守松
LI Wei;ZHANG Liang-jie;LI Dong-dong;ZHAO Shou-song(Dept.of Infectious Diseases,First Affiliated Hospital of Bengbu Medical College,Bengbu 233004,China)
出处
《泰山医学院学报》
CAS
2021年第1期37-40,共4页
Journal of Taishan Medical College
基金
蚌埠医学院科技发展基金(BYKF1739)。
关键词
肝肿瘤
化疗
奥沙利铂
氟尿嘧啶
亚叶酸钙
Liver neoplasms
chemotherapy
oxaliplatin
fluorouracil
leucovorin
